Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial-Reference-Cited by-同舟云学术

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Published:2015-06 Issue:6 Volume:26 Page:1201-1207
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Passardi A.,Nanni O.,Tassinari D.,Turci D.,Cavanna L.,Fontana A.,Ruscelli S.,Mucciarini C.,Lorusso V.,Ragazzini A.,Frassineti G.L.,Amadori D.

Funder

FARM6FJJAY

Italian Medicines Agency

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/6/1201/16699898/mdv130.pdf

Reference21 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer;Scheithauer;BMJ,1993

3. Overview of systemic therapy for colorectal cancer;Goodwin;Clin Colon Rectal Surg,2009

4. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

5. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale;Colucci;J Clin Oncol,2005

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives;Cancers;2024-02-22

2. Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial;JCO Precision Oncology;2024-02

3. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis;BMC Gastroenterology;2024-02-01

4. Anti‐angiogenesis in colorectal cancer therapy;Cancer Science;2024-01-17

5. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis;Cancer Medicine;2023-12